$COR · Cencora, Inc.
Cencora reported Q4 and full-year FY2026 results ended September 30, 2026. Q4 revenue rose 5.5% to $88.4B; GAAP diluted EPS was $2.71 versus $(1.75) a year ago, and adjusted diluted EPS rose 21.4% to $4.66. Full-year revenue rose 5.0% to $337.4B, with GAAP EPS of $17.95 and adjusted EPS of $17.97. The company introduced FY2027 adjusted EPS guidance of $19.40-$19.75 (8%-10% growth), raised its quarterly dividend 10% to $0.66 per share, and announced a new reportable segment structure.
- Q4 revenue $88.4B, up 5.5% year over year.
- Q4 adjusted diluted EPS $4.66, up 21.4% from $3.84.
- FY2026 revenue $337.4B, up 5.0%; adjusted EPS $17.97, up 12.3%.
- FY2027 adjusted EPS guidance $19.40-$19.75, implying 8%-10% growth.
- Quarterly dividend raised 10% to $0.66 per share, payable November 30, 2026.
Extended-hours last trade $338.00, down 0.73% vs the $340.50 regular close, despite the earnings beat and raised guidance.
Cencora delivered a strong quarter with 21.4% adjusted EPS growth and raised FY2027 guidance, while restructuring into new segments and boosting its dividend 10%.
Cencora's OneOncology acquisition (February 2026) and new specialty/provider-services segment reflect the pharma distribution sector's push into higher-margin oncology and provider services.
GLP-1 sales carry lower gross margins, pressuring profitability; higher net interest expense ($136.3M in Q4, up $58.5M) reflects debt taken on for the OneOncology acquisition.